Bishop is bullish on eResearch because of its rapid growth, driven by its dominance of centralized cardiographic monitoring of patients participating in clinical drug trials.

FORBES: Portfolio Defibrillator

The Food and Drug Administration has been emphatic about its preference for centralized cardiograph monitoring, and drug and biotech companies, in effect, are forced to utilize this technology to streamline new drug approvals.

FORBES: Portfolio Defibrillator